Figures & data
Figure 1 Difluprednate molecule.
Figure 2 Phase 3 postoperative trial: Percent of subjects with clinical response (anterior chamber cell count ≤5 and flare grade 0).
Figure 3 Phase 3 uveitis trial. Mean anterior chamber (AC) cell score over time.
Figure 4 Phase 3 open-label refractory uveitis trial. Anterior chamber (AC) cell score mean change from baseline.
Figure 5 Phase 3 open-label refractory uveitis trial. Percent of patients with anterior chamber (AC) cell score of 0 or 1.
Figure 6 Sirion phase 3 uveitis trial: anterior chamber (AC) cell score change over time.
Figure 7 Sirion phase 3 uveitis trial: pain score – mean change from baseline.
